Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. - Ngo HX; Xu AY; Velásquez GE; Zhang N; Chang VK; Kurbatova EV; Whitworth WC; Sizemore E; Bryant K; Carr W; Weiner M; Dooley KE; et al. (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024)